2 results
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
Approved WMORecruiting
To study the effectiveness of physiotherapy plus an eHealth psychological intervention targeted at psychosocial risk factors compared to usual physiotherapy care on disability, for patients at risk of developing persistent low back pain and neckā¦